Biocon Limited
2,320words
0turns
0analyst exchanges
0executives
Key numbers — 29 extracted
rs,
5, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National
₹1,200
und raise to pare down debt Structured funding provided by Kotak Strategic Situations fund (up to ₹1,200 Cr) Part of recent stake sale in Syngene – Biocon maintains majority control at 54.9% B I O C O N
54.9%
fund (up to ₹1,200 Cr) Part of recent stake sale in Syngene – Biocon maintains majority control at 54.9% B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 5 5 Opening Remar
1,069
%
Y23 Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Total Revenue 3,020 2,223 Core EBITDA1 1,069 % Margin EBITDA % Margin Profit Before Tax (Before exceptional charge) % Margin Net Profit (Bef
36%
(Before exceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +5
24%
ceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Resea
8%
charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23%
5%
% Margin Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generic
33%
Net Profit (Before exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generics +18% Ne
12%
exceptional charge) Net Profit Margin % 36% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generics +18% Net R&D spend at ₹337C
54%
% 723 24% 246 8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generics +18% Net R&D spend at ₹337Cr, up ₹199 Cr vs Q3 FY22 Forex Loss of ₹44Cr
23%
8% 140 5% 715 33% 537 24% 269 12% 187 8% 36 49 35 (9) Biosimilars +54% | Research +23% | Generics +18% Net R&D spend at ₹337Cr, up ₹199 Cr vs Q3 FY22 Forex Loss of ₹44Cr vs gain of ₹19
Advertisement